PatientsVille.com Logo


Depakote Medical Research Studies

Up-to-date List of Depakote Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Depakote Medical Research Studies

Rank Status Study
1 Recruiting A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets
Condition: Epilepsy
Interventions: Drug: Divalproex Sodium Extended-release 250mg;   Drug: Depakote 250mg
Outcome Measure: Evaluate generic divalproex sodium extended release to Depakote ER
2 Recruiting Valproic Acid for the Prevention of Post-Amputation Pain
Conditions: Pain, Phantom;   Pain, Neuropathic
Interventions: Drug: Valproic Acid;   Other: Cherry Syrup
Outcome Measures: Efficacy of Valproic Acid in reducing the Incidence of chronic neuropathic and post-amputation pain.;   Neuropathic limb or post-amputation pain, and the incidence of pain sub-types;   Effect on analgesic requirement;   Qualitative characterization of pain sub-types
3 Recruiting Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
Outcome Measures: Maximum Tolerated Dose (MTD) of Bevacizumab and Temsirolimus and/or Cetuximab or Valproic Acid;   Tumor Response
4 Unknown  Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Valproic acid
Outcome Measures: Best clinical response as defined by NCIWG criteria for CLL;   Hematological toxicity (graded according to NCIWG criteria for CLL);   Non- hematological toxicity (graded according to NCI common toxicity criteria)
5 Recruiting Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot
Condition: Cancer
Intervention: Drug: Valproic Acid
Outcome Measures: Determine if valproic acid levels correlate with histone acetylation in leukocytes during treatment and whether either valproic acid levels or histone acetylation in leukocytes predict histone acetylation in tumor samples post treatment.;   Assess the sensitivity and specificity of the genomic sensitivity signature of VPA (GDSS-VPA) to predict histologically measured antitumor activity of valproic acid in newly diagnosed breast cancer.;   Analyze the change in immunohistochemical markers of proliferation, apoptosis, and tumor grade following treatment with valproic acid in newly diagnosed breast cancer.;   Analyze the change in radiologic markers of tumor size and vascularity following treatment with valproic acid in newly diagnosed breast cancer;   Analyze whether intrinsic breast subtype by the Breast Bioclassifier correlates with changes in tumor proliferation rate or changes in DCE-MRI markers of size and vascularity following treatment with valproic acid.;   Determine if women have dose-limiting toxicities for valproic acid over 7-12 days
6 Recruiting Valproate and Levocarnitine in Children With Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Interventions: Drug: Valproate, Levocarnitine;   Drug: Placebo
Outcome Measures: Change in muscle power on a 5 point scale as per the principles of manual muscle testing at 12, 24, 36 and 52 weeks;   a) Change in functional measure using modified Hammersmith Functional Motor Scale (MHFMS) score at 12, 24, 36 and 52 weeks 12, 24, 36 and 52 weeks.
7 Recruiting Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
Conditions: Hematuria;   Bladder Cancer
Intervention: Drug: Valproic Acid
Outcome Measures: Thrombospondin-1 gene expression;   Angiogenesis, proliferation, and histone deacetylase activity markers
8 Recruiting A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Condition: Thyroid Neoplasm
Intervention: Drug: Valproic Acid
Outcome Measures: To determine if valproic acid will inhibit thyroid cancer growth, as evidenced by a decrease in thyroglobulin level, and tumor size.;   To determine if valproic acid therapy will induce differentiation of and therefore increase uptake of radioactive iodine by the tumor cells. To determine the effect of valproic acid on differentiation markers.
9 Not yet recruiting Efficacy Study of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.
Conditions: Generalized Convulsive Status Epilepticus;   Intensive Care Unit
Interventions: Drug: Intravenous Sodium Valproate;   Drug: Placebo
Outcome Measures: Number of patients in ICU for a GCSE discharged alive from the hospital at Day 15.;   Frequency of refractory status epilepticus;   Morbidity related to ICU stay;   Cognitive dysfunction
10 Unknown  Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote
Conditions: Epilepsy;   Behavioral Disturbance
Intervention: Procedure: Rapid versus slow conversion
Outcome Measures: Between group comparisons of GI and CNS side effect burden;   Between group comparison of Quality of Life as measured bye the QOLIE-89;   Between group comparison of trough Total and Free valproic acid serum levels
11 Not yet recruiting Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium
Condition: Autism
Interventions: Drug: divalproex sodium;   Other: Placebo
Outcome Measures: effect of drug vs placebo on reduction in epileptiform EEG discharges in children with ASD;   behavior changes in drug vs placebo.
12 Not yet recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
Outcome Measures: Overall survival;   Relapse-free survival;   Tolerability
13 Unknown  Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment
Conditions: Epilepsy;   Adverse Effects
Interventions: Drug: valproate sodium;   Genetic: Polymorphism Analysis;   Other: Pharmacokinetic analysis
Outcome Measure: epileptic seizure
14 Recruiting Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Conditions: Acute Myelogenous Leukemia AML;   Myelodysplastic Syndrome MDS
Intervention: Drug: Vidaza and Valproic Acid
Outcome Measures: Survival;   Disease Relapse
15 Recruiting Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Conditions: Sarcoma;   Soft Tissue Sarcoma;   Locally Advanced Sarcoma;   Unresectable Sarcoma;   Metastatic Sarcoma
Intervention: Drug: Bevacizumab, Gemcitabine, docetaxel and valproic acid
Outcome Measure: Dose-limiting toxicities per CTCAE 4.0; grade 4 hematologic toxicity; grade 3 or 4 hepatotoxicity.
16 Recruiting A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers or Trauma Patients
Conditions: Healthy Individuals Safety Study;   Shock,Hemorrhagic
Interventions: Drug: Valproic Acid;   Drug: Isotonic saline solution
Outcome Measure: Dose limiting toxicity (DLT)
17 Recruiting Trial of Oral Valproic Acid for Retinitis Pigmentosa
Condition: Retinitis Pigmentosa
Interventions: Drug: Valproic Acid;   Drug: Placebo
Outcome Measures: Mean change in visual field area from baseline to 52 weeks.;   Static perimetry measurements in the full visual field;   Mean change in best corrected visual acuity.;   Color contrast sensitivity;   Mean change in peak Electroretinogram (ERG) amplitude;   Mean change in central macular thickness and macular volume;   Change in fundus appearance;   Mean change in total score on vision-related quality of life.;   Changes in clinical laboratory data;   Changes in physical examination findings
18 Unknown  Determining Metabolic Effects of Valproate and Antipsychotic Therapy
Condition: Schizophrenia
Interventions: Drug: Valproate;   Drug: Placebo
Outcome Measures: Oral glucose tolerance test (fsOGTT) and hyperinsulinemic pancreatic clamp;   Body composition using dual energy x-ray absorptiometry, magnetic resonance scans, and anthropomorphic measurements
19 Recruiting Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Valproate;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
Outcome Measure: Establishment of maximum tolerable dose of valproate.
20 Not yet recruiting Valproic Acid (VPA) vs Placebo
Condition: Breast Cancer
Interventions: Drug: Placebo;   Drug: Valproic Acid (VPA);   Behavioral: Questionnaires;   Behavioral: Pill Diary;   Behavioral: Drainage Diary
Outcome Measure: Time to Pleural Catheter Removal

These studies may lead to new treatments and are adding insight into Depakote etiology and treatment.

A major focus of Depakote research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Depakote